Results 301 to 310 of about 554,589 (315)

Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials

European Journal of Neurology, 2014
Dopamine agonists (DAs) are generally considered to be deprived of the highly dyskinetic effect of levodopa in Parkinson's disease (PD) patients. However, the risk for dyskinesia induced by DA monotherapy and the contribution of clinically significant ...
Chondrogiorgi M, Tatsioni A, Reichmann H, Konitsiotis S Dopamine   +3 more
semanticscholar   +1 more source

A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole.

American Journal on Addictions, 2014
BACKGROUND Buprenorphine, used for treating opioid dependence, may have a withdrawal syndrome requiring treatment. Modulation of the dopamine system, which has been implicated in opioid withdrawal, may be a target for withdrawal for opioids such as ...
M. Makhinson, Juliana Gomez-Makhinson
semanticscholar   +1 more source

Temozolomide in the management of dopamine agonist–resistant prolactinomas

Clinical Endocrinology, 2012
The majority of prolactinomas respond to dopamine agonist therapy, but a proportion are resistant, requiring other treatments including surgery and/or radiotherapy.
B. Whitelaw, D. Dworakowska, N. Thomas, S. Barazi, P. Riordan-Eva, A. King, Tim Hampton, David Landau, D. Lipscomb, C. Buchanan, J. Gilbert, S. Aylwin   +11 more
semanticscholar   +1 more source

Dopamine agonist use and the risk of heart failure

Pharmacoepidemiology and Drug Safety, 2012
A potential risk of heart failure was recently observed in randomized trials of the dopamine agonist pramipexole. The extent of the risk with this and other dopamine agonists is unknown.
C. Renoux, S. Dell'aniello, J. Brophy, S. Suissa   +3 more
semanticscholar   +1 more source

Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans

Synapse, 2012
The features of schizophrenia are consistent with increased sensitivity to endogenous dopamine. Animal models of schizophrenia reveal an increase in the in vitro proportion of striatal dopamine D2 receptors in the high‐affinity state for dopamine (i.e ...
P. Seeman
semanticscholar   +1 more source

Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma

Clinical Endocrinology, 2011
Context  The optimal duration of dopamine agonist (DA) therapy in prolactinoma is unknown. There are concerns that despite low recurrence rates in highly selected groups, high recurrence rates after DA withdrawal may occur in routine practice.
T. Barber, J. Kenkre, C. Garnett, R. Scott, J. Byrne, J. Wass   +5 more
semanticscholar   +1 more source

The Emergence of Devastating Impulse Control Disorders During Dopamine Agonist Therapy of the Restless Legs Syndrome

Clinical neuropharmacology, 2011
Introduction:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with ...
D. Dang, D. Cunnington, J. Swieca
semanticscholar   +1 more source

Dopamine agonist withdrawal syndrome in Parkinson disease.

Archives of Neurology, 2010
OBJECTIVES To report and characterize a dopamine agonist (DA) withdrawal syndrome (DAWS) in Parkinson disease. DESIGN Retrospective cohort study. SETTING Outpatient tertiary movement disorders clinic. Patients A cohort of 93 nondemented patients with
Christina A. Rabinak, M. Nirenberg
semanticscholar   +1 more source

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

Science, 1990
The striatum, which is the major component of the basal ganglia in the brain, is regulated in part by dopaminergic input from the substantia nigra. Severe movement disorders result from the loss of striatal dopamine in patients with Parkinson's disease ...
C. Gerfen, T. Engber, L. Mahan, Z. Susel, T. Chase, F. Monsma, D. Sibley   +6 more
semanticscholar   +1 more source

Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy, 2010
Importance to the field: There is a large unmet need for new therapies to treat type 2 diabetes (T2DM) which reduce fasting and postprandial glucose without increasing insulin levels and which are not associated with weight gain or hypoglycemia.
R. Scranton, A. Cincotta
semanticscholar   +1 more source